File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Primary B cell lymphoma of the mediastinum

TitlePrimary B cell lymphoma of the mediastinum
Authors
Issue Date1996
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1996, v. 14 n. 4, p. 173-179 How to Cite?
AbstractPrimary B cell mediastinal lymphoma has been recognized as a distinct entity recently. This is a retrospective study to define the clinical features and treatment outcome over a 10-year period. Twenty-four consecutive patients (male/female: 11/13) with B cell lymphoma primarily involving the mediastinum were studied. The median age was 34 years. Symptoms were mainly referrable to the chest, with superior vena cava syndrome (SVCO) present in one-third of the patients. Bulky disease was present in over half (58 per cent) and B symptoms were present in 38 per cent of patients. The overall CR rate was 70 per cent and the 5-year OS rates were 56 per cent and 72 per cent for all and CR patients respectively. Five (71 per cent) primary refractory patients and four (66 per cent) relapsed patients died despite salvage therapy. Six relapses occurred at a median of 6 months from treatment. This study showed that primary large B cell lymphoma of the mediastinum is a clinically distinct entity affecting young patients. A significant proportion attained CR and overall, more than half achieved prolonged remission, and most of the relapses occurred early. However, those who failed to attain CR or relapsed still had a poor outcome. An intensive therapy such as autologous bone marrow transplant has to be considered in this subgroup of patients.
Persistent Identifierhttp://hdl.handle.net/10722/77046
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorChan, ACLen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorHo, FCSen_HK
dc.contributor.authorTodd, Den_HK
dc.date.accessioned2010-09-06T07:27:41Z-
dc.date.available2010-09-06T07:27:41Z-
dc.date.issued1996en_HK
dc.identifier.citationHematological Oncology, 1996, v. 14 n. 4, p. 173-179en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77046-
dc.description.abstractPrimary B cell mediastinal lymphoma has been recognized as a distinct entity recently. This is a retrospective study to define the clinical features and treatment outcome over a 10-year period. Twenty-four consecutive patients (male/female: 11/13) with B cell lymphoma primarily involving the mediastinum were studied. The median age was 34 years. Symptoms were mainly referrable to the chest, with superior vena cava syndrome (SVCO) present in one-third of the patients. Bulky disease was present in over half (58 per cent) and B symptoms were present in 38 per cent of patients. The overall CR rate was 70 per cent and the 5-year OS rates were 56 per cent and 72 per cent for all and CR patients respectively. Five (71 per cent) primary refractory patients and four (66 per cent) relapsed patients died despite salvage therapy. Six relapses occurred at a median of 6 months from treatment. This study showed that primary large B cell lymphoma of the mediastinum is a clinically distinct entity affecting young patients. A significant proportion attained CR and overall, more than half achieved prolonged remission, and most of the relapses occurred early. However, those who failed to attain CR or relapsed still had a poor outcome. An intensive therapy such as autologous bone marrow transplant has to be considered in this subgroup of patients.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic useen_HK
dc.subject.meshDisease-Free Survivalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLymphoma, B-Cell - drug therapy - pathologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMediastinal Neoplasms - drug therapy - pathologyen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshSex Characteristicsen_HK
dc.titlePrimary B cell lymphoma of the mediastinumen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0361-8609&volume=14&spage=173&epage=9&date=1997&atitle=Primary+B+Cell+lymphoma+of+the+mediastinum.en_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/(SICI)1099-1069(199612)14:4<173::AID-HON588>3.0.CO;2-Wen_HK
dc.identifier.pmid9267463-
dc.identifier.scopuseid_2-s2.0-0030417293en_HK
dc.identifier.hkuros33003en_HK
dc.identifier.hkuros24716-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030417293&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue4en_HK
dc.identifier.spage173en_HK
dc.identifier.epage179en_HK
dc.identifier.isiWOS:A1996XQ93300003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridChan, ACL=16047349300en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridHo, FCS=7103408147en_HK
dc.identifier.scopusauthoridTodd, D=7201388182en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats